3 Psychedelic Sector Leaders That Investors Need To Be Aware OfPsyched Wellness Announces New OTCQB Ticker: PSYCF2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private Placement

Technical420 Site Search

Returned 12 result(s).

Havn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an Authorized Products Listing

Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds, the development of a full range of natural healthcare products, and innovative mental health treatment, is pleased to announce a product listing agreement for a range of Havn Life's natural health products,…

Havn Life Sciences to Supply Psychedelic Compounds to Clinical Studies Focused on Veterans and PTSD

Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind, is pleased to announce it has signed a…

MushroomStocks.com Deep Dive: HAVN Life Sciences

The 2020 election proved to be a major catalyst for the psychedelic therapy market and we have noticed a significant spike in interest in the sector. The main driver behind the increased interest is the legislation that was passed in Oregon that decriminalized psilocybin. We are starting to see similarities…

Havn Life Announces Launch of a Range of Natural Health Products

Havn Life Sciences Inc. (CNSX:HAVN) (FRA:5NP), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce its initial seven natural health supplements. These 7 products will be Havn Life's first natural health products to launch…

HAVN Life Sciences Has Been One Of The Best Performing Stocks In The Psychedelics Sector Over The Past Month

Last month, Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) commenced trading on the Canadian Stock Exchange (CSE) and is an opportunity that we have been closely following. We consider Havn Life to be an attractive play on the burgeoning psychedelic therapy market and believe that the opportunity is flying under the…

Havn Life Sciences Signs Agreement to Supply Psychedelic Compounds for use in Research and Development to Revive Therapeutics

Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has signed an agreement to supply Revive Therapeutics Ltd. (CSE:RVV, USA:RVVTF) with psychedelic compounds for use in investigational new drug…

Havn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, Respectively, and the Acceleration of Warrants

Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the "Board"). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having served…

Havn Life joins UK Psychedelics Working Group with Leading International Scientists

Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has joined the Drug Science Medical Psychedelics Working Group consortium. The working group was…

HAVN Life Sciences Is Off To A Great Start Out Of The Gate

Last week, Havn Life Sciences Inc. (CSE:HAVN) commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol HAVN. The biotech company has been focused on the development of standardized psychoactive compounds that are derived from plants and fungi for use in research and is an opportunity that we…

Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE

Havn Life Sciences Inc. (CSE:HAVN), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has commenced trading on the Canadian Securities Exchange ("CSE") under the ticker symbol "HAVN". "Listing on the Canadian…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link